Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma

Author(s): Domenico Ribatti and Angelo Vacca

Volume 1, Issue 2, 2004

Page: [135 - 136] Pages: 2

DOI: 10.2174/1570180043485491

Price: $65

Abstract

Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their microenvironment. Multiple myeloma is so far the most responsive malignancy.

Keywords: angiogenesis, antiangiogenesis, multiple myeloma, thalidomide


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy